Advertisement

Topics

Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma

2016-09-22 21:08:21 | BioPortfolio

Summary

The goal of this clinical research study is to learn if nivolumab and trametinib (with or without dabrafenib) can help to control metastatic melanoma in patients who have a BRAF, NRAS, or BRAF-wild-type mutation.

The safety of these drug combinations will also be studied.

Description

Study Groups:

If you are found to be eligible to take part in this study, you will be assigned to 1 of 2 study groups based on the type of mutation you have.

- If you are in Group A, you will receive nivolumab, dabrafenib, and trametinib (BRAF-mutated patients).

- If you are in Group B, you will receive nivolumab and trametinib (BRAF-wild-type or NRAS-mutation patients).

You and the study staff will know which group you have been assigned.

Study Drug Administration:

Each study cycle is 4 weeks.

You will take trametinib by mouth every day while you are on study. Each dose should be taken about 12 hours apart (1 dose in the morning, 1 dose in the evening) with a cup of water (about 8 ounces), either 1 hour before or 2 hours after a meal.

You will also receive nivolumab by vein over about 30 minutes on Days 1 and 15 of each cycle.

If you are in Group A, you will also take dabrafenib at the same time you take your dose of trametinib.

If you vomit after your dose of study drugs, do not retake the dose. Wait until your next scheduled dose. If you are in Group A and you miss a dose of dabrafenib, you may take the dose as soon as you remember, as long as your next dose is more than 6 hours later. If you miss a dose of trametinib, you may take the dose as soon as you remember as long as the next dose is scheduled for at least 12 hours later.

Length of Study:

You may continue taking the study drugs for as long as the doctor thinks it is in your best interest. You will no longer be able to take the study drugs if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions.

Your participation in this study will be over after about 3 years of follow-up (described below).

Study Visits:

During Week 1 of Cycle 1:

- You will have a physical exam, including a skin exam.

- Blood (about 5 teaspoons) will be drawn for routine tests and to check your autoimmune status.

During Weeks 2 and 4 of Cycles 1-3 and Week 3 of Cycle 3, blood (about 3 teaspoons) will be drawn for routine tests.

During Week 3 of Cycle 1:

- You will have a physical exam, including a skin exam.

- Blood (about 3 teaspoons) will be drawn for routine, PD, and PBMC testing.

During Week 1 of Cycle 2:

- You will have a physical exam, including a skin exam.

- You will have an EKG.

- You will have an eye exam.

- Blood (about 5 teaspoons) will be drawn for routine and pharmacokinetic (PK) testing before your dose of study drug. PK testing measures the amount of study drug in the body at different time points.

During Week 3 of Cycle 2:

- You will have a physical exam, including a skin exam.

- Blood (about 3 teaspoons) will be drawn for routine tests.

During Week 1 of Cycles 3 and beyond:

- You will have a physical exam, including a skin exam.

- You will have an EKG.

- Blood (about 3 teaspoons) will be drawn for routine tests. During Cycle 3, this blood sample will also be used for PD and PBMC testing.

At Months 3 and 6 and then every year after that (if the study doctor thinks it is needed), you will have an eye exam.

Every 12 weeks:

- You will have an MRI or CT scan.

- You will have an ECHO.

End-of-Treatment Visit:

About 30 days after your last dose of study drugs:

- You will have a physical exam.

- You will have an EKG.

- Blood (about 2 teaspoons) will be drawn for routine, PD, and PBMC testing.

- You will have an MRI or CT scan.

- If the study doctor thinks it is needed, you will have an eye exam.

Long-Term Follow-Up:

After you stop taking the study drugs, the study doctor or study staff will continue to check on your health every 3 months for up to 3 years. This information may be collected at your routine, standard of care clinic visits; it may be collected from your medical records; or you may be called by the study staff and asked. If you are called, it should take about 10 minutes.

Your participation will be over after you have completed long-term follow-up.

This is an investigational study. Nivolumab, trametinib, and dabrafenib are each FDA approved and commercially available for the treatment of melanoma. However, it is considered investigational to use these drugs in combination with each other to treat melanoma. The study doctor can explain how the study drugs are designed to work.

Up to 60 participants will be enrolled in this study. All will take part at MD Anderson.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Melanoma

Intervention

Nivolumab, Dabrafenib, Trametinib

Location

University of Texas MD Anderson Cancer Center
Houston
Texas
United States
77030

Status

Not yet recruiting

Source

M.D. Anderson Cancer Center

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-09-22T21:08:21-0400

Clinical Trials [1335 Associated Clinical Trials listed on BioPortfolio]

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

This randomized phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabra...

Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

Dabrafenib and trametinib are drugs that are usually given for the treatment of melanoma. Combinations of dabrafenib and trametinib have also been studied and when used together have shown...

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

The purpose of this study is to determine the maximum tolerated dose and the safety profile of MEDI4736 in combination with dabrafenib and trametinib or with trametinib alone in subjects w...

Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

This randomized phase II trial studies how well dabrafenib and trametinib work in treating patients with stage III-IV melanoma that cannot be removed by surgery and contains a B-Raf proto-...

Study for the Evaluation Dabrafenib (Tafinlar) and Trametinib (Mekinist) Plus DNE3 in Patients With Metastatic Melanoma

Previous studies have shown that combination of a BRAF inhibitor (dabrafenib) with MEK inhibitor (trametinib) and exhibit synergistic effects on tumor cells (melanoma), together with Akt i...

PubMed Articles [994 Associated PubMed Articles listed on BioPortfolio]

Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.

Patients with brain metastases (BM) from melanoma have an overall survival (OS) of 2-6 months after whole-brain radiotherapy. Targeted therapy (TT) is an effective treatment for BRAF-mutated metastati...

Success of rechallenging dabrafenib and trametinib combination therapy after trametinib-induced rhabdomyolysis: a case report.

The mitogen-activated protein kinase pathway regulates cell growth and differentiation and is activated by BRAF mutations. BRAF mutations are present in about 40-50% of cutaneous melanomas. More than ...

Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma.

Explore the heterogeneity in dynamics of tumour response to vemurafenib, dabrafenib and trametinib using routinely collected clinical trial imaging data.

Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study.

The main objective of the study was to evaluate the efficacy and safety of dabrafenib alone or combined with trametinib for compassionate use in patients with metastatic melanoma.This retrospective, o...

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.

Dual BRAF and MEK inhibition produces a response in a large number of patients with stage IV BRAF-mutant melanoma. The existing standard of care for patients with clinical stage III melanoma is upfron...

Medical and Biotech [MESH] Definitions

An unpigmented malignant melanoma. It is an anaplastic melanoma consisting of cells derived from melanoblasts but not forming melanin. (Dorland, 27th ed; Stedman, 25th ed)

Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA.

A cellular subtype of malignant melanoma. It is a pigmented lesion composed of melanocytes occurring on sun-exposed skin, usually the face and neck. The melanocytes are commonly multinucleated with a "starburst" appearance. It is considered by many to be the in situ phase of lentigo maligna melanoma.

Found in large amounts in the plasma and urine of patients with malignant melanoma. It is therefore used in the diagnosis of melanoma and for the detection of postoperative metastases. Cysteinyldopa is believed to be formed by the rapid enzymatic hydrolysis of 5-S-glutathionedopa found in melanin-producing cells.

A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.

More From BioPortfolio on "Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...

Melanoma
Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes. Metastasis to other regions of the body is also common....

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Searches Linking to this Trial